open access

Vol 18, No 3 (2021)
Review paper
Published online: 2021-07-13
Get Citation

Neuropsychiatric complications related to COVID-19: clinical review

Jadwiga Mosiołek1, Paweł Jakubczak2, Anna Mosiołek32
DOI: 10.5603/PSYCH.2021.0022
·
Psychiatria 2021;18(3):232-240.
Affiliations
  1. Uniwersytet Medyczny we Wrocławiu
  2. Mazowieckie Specjalistyczne Centrum Zdrowia im. Prof. Jana Mazurkiewicza, Pruszków, Poland
  3. Klinika Psychiatryczna Wydział Nauki o Zdrowiu Warszawski Uniwersytet Medyczny

open access

Vol 18, No 3 (2021)
Prace poglądowe - nadesłane
Published online: 2021-07-13

Abstract

COVID-19 is a disease caused by infection with the SARS-CoV-19 virus which was first detected in 2019. Since
then it has spread around the world, leading to the declaration of the coronavirus pandemic by the World Health
Organization. The course of infection may take a wide variety of forms from asymptomatic to severe with the
presence of numerous complications that can lead to death. Symptoms of infection may affect various organs
and systems, especially the respiratory system. In our article, we will focus on the neuropsychiatric consequences
of SARS-CoV-2 infection. The most frequently reported neurological symptoms include headache (3.7–70.3%)
and chronic fatigue (53.1–53.6%). The dominant psychiatric symptoms are anxiety and depressive symptoms
(4.6–37.86%). At the moment, however, the long-term consequences of SARS-CoV-19 infection are still unknown,
therefore further observation and research in this direction is necessary.

Abstract

COVID-19 is a disease caused by infection with the SARS-CoV-19 virus which was first detected in 2019. Since
then it has spread around the world, leading to the declaration of the coronavirus pandemic by the World Health
Organization. The course of infection may take a wide variety of forms from asymptomatic to severe with the
presence of numerous complications that can lead to death. Symptoms of infection may affect various organs
and systems, especially the respiratory system. In our article, we will focus on the neuropsychiatric consequences
of SARS-CoV-2 infection. The most frequently reported neurological symptoms include headache (3.7–70.3%)
and chronic fatigue (53.1–53.6%). The dominant psychiatric symptoms are anxiety and depressive symptoms
(4.6–37.86%). At the moment, however, the long-term consequences of SARS-CoV-19 infection are still unknown,
therefore further observation and research in this direction is necessary.

Get Citation

Keywords

COVID-19, neuropsychiatric sequelae, neuroinvasion

About this article
Title

Neuropsychiatric complications related to COVID-19: clinical review

Journal

Psychiatria (Psychiatry)

Issue

Vol 18, No 3 (2021)

Article type

Review paper

Pages

232-240

Published online

2021-07-13

DOI

10.5603/PSYCH.2021.0022

Bibliographic record

Psychiatria 2021;18(3):232-240.

Keywords

COVID-19
neuropsychiatric sequelae
neuroinvasion

Authors

Jadwiga Mosiołek
Paweł Jakubczak
Anna Mosiołek

References (47)
  1. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int (24.03.2021).
  2. Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020; 41(12): 1100–1115.
  3. McAloon C, Collins Á, Hunt K, et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. BMJ Open. 2020; 10(8): e039652.
  4. Xie P, Ma W, Tang H, et al. Severe COVID-19: A review of recent progress with a look toward the future. Front Public Health. 2020; 8: 189.
  5. Nuzzo D, Picone P. Potential neurological effects of severe COVID-19 infection. Neurosci Res. 2020; 158: 1–5.
  6. Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021; 76(2): 428–455.
  7. Zhou Y, Chi J, Lv W, et al. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2021; 37(2): e3377.
  8. Meo SA, Alhowikan AM, Al-Khlaiwi T, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020; 24(4): 2012–2019.
  9. Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bulletin of the World Health Organization 2021. 2021; 99: 19–33.
  10. Su YJ, Lai YC. Comparison of clinical characteristics of coronavirus disease (COVID-19) and severe acute respiratory syndrome (SARS) as experienced in Taiwan. Travel Med Infect Dis. 2020; 36: 101625.
  11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223): 497–506.
  12. Wang D, Hu Bo, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–1069.
  13. Halaji M, Farahani A, Ranjbar R, et al. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. Infez Med. 2020; 28(suppl 1): 6–17.
  14. Zhu Z, Lian X, Su X, et al. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020; 21(1): 224.
  15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020; 395(10229): 1054–1062.
  16. Rogers J, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry. 2020; 7(7): 611–627.
  17. Abboud H, Abboud FZ, Kharbouch H, et al. COVID-19 and SARS-Cov-2 infection: pathophysiology and clinical effects on the nervous system. World Neurosurg. 2020; 140: 49–53.
  18. Azim D, Nasim S, Kumar S, et al. Neurological consequences of 2019-nCoV infection: A comprehensive literature review. Cureus. 2020; 12(6): e8790.
  19. Yachou Y, El Idrissi A, Belapasov V, et al. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci. 2020; 41(10): 2657–2669.
  20. Baig AM, Khaleeq A, Ali U, et al. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020; 11(7): 995–998.
  21. Armocida D, Palmieri M, Frati A, et al. How SARS-Cov-2 can involve the central nervous system. A systematic analysis of literature of the department of human neurosciences of Sapienza University, Italy. J Clin Neurosci. 2020; 79: 231–236.
  22. Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020; 80(4): 401–406.
  23. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 683–690.
  24. Nalleballe K, Reddy Onteddu S, Sharma R, et al. Spectrum of neuropsychiatric manifestations in COVID-19. Brain Behav Immun. 2020; 88: 71–74.
  25. Lechien JR, Chiesa-Estomba CM, Place S, et al. COVID-19 Task Force of YO-IFOS. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020; 288(3): 335–344.
  26. Liguori C, Pierantozzi M, Spanetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav Immun. 2020; 88: 11–16.
  27. Ye M, Ren Yi, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun. 2020; 88: 945–946.
  28. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020; 94: 55–58.
  29. Efe IE, Aydin OU, Alabulut A, et al. COVID-19-associated encephalitis mimicking glial tumor. World Neurosurg. 2020; 140: 46–48.
  30. Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology. 2020; 296(2): E119–E120.
  31. Hayashi M, Sahashi Y, Baba Y, et al. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci. 2020; 415: 116941.
  32. Delorme C, Paccoud O, Kas A, et al. CoCo-Neurosciences study group and COVID SMIT PSL study group. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol. 2020; 27(12): 2651–2657.
  33. Kishfy L, Casasola M, Banankhah P, et al. Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19. J Neurol Sci. 2020; 414: 116943.
  34. Princiotta Cariddi L, Tabaee Damavandi P, Carimati F, et al. Reversible encephalopathy syndrome (PRES) in a COVID-19 patient. J Neurol. 2020; 267(11): 3157–3160.
  35. Chen T, Wu Di, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368: m1091.
  36. Huang KJ, Su IJ, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005; 75(2): 185–194.
  37. Caress JB, Castoro RJ, Simmons Z, et al. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve. 2020; 62(4): 485–491.
  38. Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020; 87: 34–39.
  39. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020; 95(8): e1060–e1070.
  40. Qi R, Chen W, Liu S, et al. Psychological morbidities and fatigue in patients with confirmed COVID-19 during disease outbreak: prevalence and associated biopsychosocial risk factors. medRxiv. 2020.
  41. Forte G, Favieri F, Tambelli R, et al. COVID-19 pandemic in the italian population: validation of a post-traumatic stress disorder questionnaire and prevalence of PTSD symptomatology. Int J Environ Res Public Health. 2020; 17(11).
  42. Johnson SU, Ebrahimi OV, Hoffart A. PTSD symptoms among health workers and public service providers during the COVID-19 outbreak. PLoS One. 2020; 15(10): e0241032.
  43. González-Sanguino C, Ausín B, Castellanos MÁ, et al. Mental health consequences during the initial stage of the 2020 Coronavirus pandemic (COVID-19) in Spain. Brain Behav Immun. 2020; 87: 172–176.
  44. Beach SR, Praschan NC, Hogan C, et al. Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement. Gen Hosp Psychiatry. 2020; 65: 47–53.
  45. Mcloughlin BC, Miles A, Webb TE, et al. Functional and cognitive outcomes after COVID-19 delirium. Eur Geriatr Med. 2020; 11(5): 857–862.
  46. Ferrando SJ, Klepacz L, Lynch S, et al. COVID-19 psychosis: A potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? Psychosomatics. 2020; 61(5): 551–555.
  47. Godeau D, Petit A, Richard I, et al. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324(6): 603–605.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl